eligibility_summary
Eligibility: Adults (≥18) with metastatic/advanced NSCLC, gastroesophageal, CRC, HCC, pancreatic, or HNSCC after progression/intolerance to standard therapy, ECOG 0–2, life expectancy ≥3 mo, measurable disease, consent required. Exclude: other active invasive cancer, hematologic malignancy, recent therapy/radiation/surgery, unstable/untreated brain mets or high‑dose steroids, bulky >7 cm, uncontrolled infection, corneal disease, QTcF>470 or LVEF<50%, active HBV/HCV, uncontrolled HIV, active TB, live vaccine <30 d, unresolved ≥G2 AEs, pregnancy/lactation, no contraception.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
NCT06515990 tests DM005 in advanced solid tumors. DM005 is a bispecific antibody–drug conjugate (ADC) built from fully human antibodies (common light chain) that simultaneously targets c‑MET (HGF receptor) and EGFR on tumor cells. Mechanism: dual receptor binding leads to ADC internalization and intracellular release of a cytotoxic payload to kill c‑MET/EGFR–expressing cells, concurrent blockade of MET and EGFR signaling may reduce proliferation and overcome resistance seen with single‑target agents. Targeted cells: tumor cells overexpressing EGFR and/or c‑MET. Targeted pathways: EGFR/ERBB and HGF/MET signaling, with downstream MAPK and PI3K/AKT pathways. IV monotherapy dosed Q3W in dose escalation/expansion (Phase 1).